A simple blood test can detect more than 50 different types of cancer with up to 99% accuracy, often before symptoms appear. The study, which examined blood tests from more than 6,000 people, was conducted by a group of American and British scientists and sponsored by a Silicon Valley startup. Scientists hope that such analyses will help to detect tumors at an early stage and treat them successfully.
The research was conducted by a group of American scientists from the Dana-Farber Institute of Oncology and Harvard Medical School, in collaboration with British scientists from the Francis Crick Institute and University College London. The results were published in the Annals of Oncology, a peer-reviewed journal published by the University of Oxford.
Although more than 99% of the analyses that detected cancer were confirmed, the scientists want to make sure that their method does not miss oncology and give false hope. This will require further research. In addition, the results of clinical trials have shown that blood analysis is better at detecting progressive oncology than the very beginning of the disease.
The analysis looks for signs of chemical changes in the genetic code – DNA – that are released into the blood from the tumor. The study included analyses of 50 different types of cancer, including rectal, ovarian, and lung cancer. In 96% of cases, the test accurately determined the type of oncology.
“We explain quickly, simply, and clearly what happened, why it matters, and what will happen next.” The number of episodes should not be changed. The end of the story: Promotional Podcasts.
The study is funded by Grail, a Silicon Valley startup whose investors include Amazon founder Jeff Bezos. “It appears that this blood test has all the necessary characteristics for widespread use as a test for various types of cancer,” says Professor Geoff Oxnard, one of the leaders of the study. “Everyone is asking when such a test will be ready. Based on successful clinical testing in thousands of patients, this test is already being introduced for limited use in clinical trials. However, the widespread application of this analysis will not be known until the results of such clinical trials are available.
“Although this analysis is still in the early stages of development, the initial results are promising,” said David Crosby, head of cancer screening research at Cancer Research UK. “Detecting cancer at its earliest stages, when it is less aggressive and more amenable to treatment, has enormous potential to save lives. However, technological innovation is critical to realizing this potential.”